%0 Journal Article
%T A single dose of angiotensin-(1-7) resolves eosinophilic inflammation and protects the lungs from a secondary inflammatory challenge.
%A Magalhaes GS
%A Gregorio JF
%A Beltrami VA
%A Felix FB
%A Oliveira-Campos L
%A Bonilha CS
%A Righetti RF
%A Tibério IFLC
%A De Sousa FB
%A Rezende BM
%A Teixeira-Carvalho A
%A Santos RA
%A Campagnole-Santos MJ
%A Rodrigues-Machado MDG
%A Teixeira MM
%A Pinho V
%J Inflamm Res
%V 73
%N 6
%D 2024 Jun 24
%M 38656426
%F 6.986
%R 10.1007/s00011-024-01880-x
%X <B>OBJECTIVE: </B>Angiotensin-(1-7) [Ang-(1-7)] is a pro-resolving mediator. It is not known whether the pro-resolving effects of Ang-(1-7) are sustained and protect the lung from a subsequent inflammatory challenge. This study sought to investigate the impact of treatment in face of a second allergic or lipopolysaccharide (LPS) challenge.<BR><B>METHODS: </B>Mice, sensitized and challenged with ovalbumin (OVA), received a single Ang-(1-7) dose at the peak of eosinophilic inflammation, 24 h after the final OVA challenge. Subsequently, mice were euthanized at 48, 72, 96, and 120 h following the OVA challenge, and cellular infiltrate, inflammatory mediators, lung histopathology, and macrophage-mediated efferocytic activity were evaluated. The secondary inflammatory stimulus (OVA or LPS) was administered 120 h after the last OVA challenge, and subsequent inflammatory analyses were performed.<BR><B>RESULTS: </B>Treatment with Ang-(1-7) resulted in elevated levels of IL-10, CD4+Foxp3+, Mres in the lungs and enhanced macrophage-mediated efferocytic capacity. Moreover, in allergic mice treated with Ang-(1-7) and then subjected to a secondary OVA challenge, inflammation was also reduced. Similarly, in mice exposed to LPS, Ang-(1-7) effectively prevented the lung inflammation.<BR><B>CONCLUSIONS: </B>A single dose of Ang-(1-7) resolves lung inflammation and protect the lung from a subsequent inflammatory challenge highlighting its potential therapeutic for individuals with asthma.